|
|
|
|
|
PEER-TO-PEER CLINICAL CONVERSATIONS |
|
|
|
|
|
|
Heterogeneity in Multifocal Prostate Cancer
|
Simpa Salami, MD, MPH
In this conversation with Alicia Morgans, Simpa Salami discusses transcriptomic heterogeneity in multifocal prostate cancer and factors predisposing certain prostate cancer-focused to metastasis.
|
|
|
|
|
|
|
|
|
|
|
|
The Molecular Biology of Prostate Cancer
|
Christopher Barbieri, MD, PhD
Christopher Barbieri joins Matthew Cooperberg for a discussion about the molecular biology of localized prostate cancer.
|
|
|
|
|
|
|
|
|
|
|
| Can Biology Help Inform Treatment Decisions In the Management of mHSPC? |
| Gert Attard, MD, PhD, FRCP |
| Gert Attard presents on whether we need more granularity in mHSPC, and whether biology can help with treatment decisions. |
|
|
|
|
|
|
|
|
|
|
|
| Into the Microverse of Prostate Cancer from Microenvironment's Immune Modulation to the Complexity of Tumour Heterogeneity |
| Emanuele Crupi, MD |
| In this presentation, Andrea Alimonti gives a talk titled, “The Role of Innate Tumor Immunity in Prostate Cancer”, and Marzia del Re discusses heterogeneity of PCa and predictive biomarkers of response and resistance. |
|
|
|
|
|
| Circulating Tumor DNA to Detect Neuroendocrine Prostate Cancer Genomic and DNA Methylation Changes
|
| Himisha Beltran, MD
|
| Circulating tumor DNA (ctDNA) may overcome some of these challenges as the collection is non-invasive, facilitating serial sampling. Himisha Beltran discusses the results of genetic and epigenetic profiling of paired tumor and ctDNA profiling from men with CRPC-PRAD and CRPC-NE.
|
|
|
|
|
|
|
|
|
|
|
| Can Biology Help Inform Treatment Decisions In the Management of mHSPC? |
| Gert Attard, MD, Ph.D., FRCP |
| In this presentation, Gert Attard discusses whether we need more granularity in mHSPC and whether biology can help with treatment decisions. |
|
|
|
|
|
| PSMA PET Tumor-to-Salivary Glands Ratio (PSG Score) To Predict Response to Lu-177 PSMA Radioligand Therapy: An International Multicenter Retrospective Study |
| Masatoshi Hotta, MD, Ph.D. |
| Masatoshi Hotta discusses the value of tumor to salivary gland uptake on PSMA PET in predicting response to Lu-177 PSMA radioligand therapy. Based on the data, PSG score is a predictive biomarker for response to Lu-177 PSMA and has comparable predictive value whether assessed quantitatively (qPSG) or qualitatively (vPSG). |
|
|
|
|
|
| Impact of Disease Status Heterogeneity of the STAMPEDE Trial Arm J Population on Oncological Outcomes in High-Risk Nonmetastatic Prostate Cancer |
| Shingo Hatakeyama, MD |
| Shingo Hatakeyama discussing the impact of disease status heterogeneity of the STAMPEDE trial arm J population on oncological outcomes in high-risk nonmetastatic prostate cancer. |
|
|
|
|
|
|
